# Test Results: literature/paper-summary.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** literature/paper-summary.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: I am a microbiome researcher reviewing literature on diet-microbiome interactions. I need a structured summary of the following paper for my literature notes.

Paper text:
[SIMULATED PAPER EXCERPT]

Title: Short-chain fatty acid production is reduced in patients with irritable bowel syndrome and correlates with symptom severity

Authors: Chen Y, Roberts K, Nakamura T, Wilson D, et al.

Abstract: Background: Irritable bowel syndrome (IBS) affects 10-15% of the global population, but its etiology remains unclear. Gut microbiome alterations have been implicated, yet functional consequences are understudied. We investigated short-chain fatty acid (SCFA) production in IBS patients versus healthy controls.

Methods: We recruited 45 IBS patients (Rome IV criteria) and 40 age- and sex-matched healthy controls. Fecal samples were analyzed using 16S rRNA gene sequencing (V4 region, Illumina MiSeq) and gas chromatography for SCFA quantification. Symptom severity was assessed using the IBS Severity Scoring System (IBS-SSS).

Results: IBS patients showed significantly reduced fecal butyrate (p=0.003) and propionate (p=0.02) compared to controls, while acetate levels were similar. Butyrate concentration negatively correlated with IBS-SSS scores (r=-0.42, p=0.004). Patients with IBS showed depletion of Faecalibacterium prausnitzii and Roseburia species, both known butyrate producers. No significant differences were observed in alpha diversity metrics (Shannon, observed ASVs).

Discussion: Our findings suggest that reduced SCFA production, particularly butyrate, may contribute to IBS symptoms. The correlation with symptom severity supports a functional role for these metabolites. Limitations include the cross-sectional design, which cannot establish causality, and recruitment from a single clinical center. Future longitudinal studies and intervention trials targeting SCFA production are warranted.

Relevance aspect: how microbial metabolites affect gut health in my mouse models

Task: Summarize this paper using the following structure.

1. **Citation**: Format as: Authors (Year). Title. Journal.

2. **Central Finding**: One to two sentences stating the main result or conclusion. Be specific about what was found, not just what was studied.

3. **Research Question/Hypothesis**: What question did the authors set out to answer?

4. **Methods Overview**:
   - Study system/organism
   - Key techniques or approaches
   - Sample size and design (if applicable)

5. **Key Results**: Three to five bullet points of specific findings. Include effect sizes or quantitative results where available.

6. **Limitations**: What limitations do the authors acknowledge? What limitations are apparent but not discussed?

7. **Open Questions**: What questions remain unanswered? What would logical next steps be?

8. **Relevance to My Work**: How might this paper inform how microbial metabolites affect gut health in my mouse models?

Constraints:
- Use only information present in the paper—do not add context from other sources
- If a section cannot be completed from the available text, state "Not available in provided text"
- Distinguish between what authors claim and what the data support
- Note if sample sizes or effect sizes are not reported

Output format: Use the numbered structure above with headers in bold.
````

## Model Output
````


**1. Citation**:  
Chen Y, Roberts K, Nakamura T, Wilson D, et al. (Year not available). Short-chain fatty acid production is reduced in patients with irritable bowel syndrome and correlates with symptom severity. Journal not available.

**2. Central Finding**:  
IBS patients had significantly lower fecal butyrate and propionate (but not acetate) compared with healthy controls, and fecal butyrate concentration was negatively correlated with IBS symptom severity. This reduction coincided with depletion of known butyrate‑producing taxa (*Faecalibacterium prausnitzii* and *Roseburia* spp.).

**3. Research Question/Hypothesis**:  
The authors set out to investigate whether short‑chain fatty acid (SCFA) production differs between IBS patients and healthy controls and whether any observed differences relate to clinical symptom severity.

**4. Methods Overview**:  
- **Study system/organism**: Human fecal samples from IBS patients (diagnosed by Rome IV criteria) and age‑ and sex‑matched healthy controls.  
- **Key techniques/approaches**: 16S rRNA gene sequencing (V4 region, Illumina MiSeq) for microbial community profiling; gas chromatography for quantification of fecal SCFAs (acetate, propionate, butyrate); IBS Severity Scoring System (IBS‑SSS) to assess symptom severity.  
- **Sample size and design**: 45 IBS patients and 40 healthy controls; cross‑sectional, case‑control design.

**5. Key Results**:  
- Fecal butyrate was significantly reduced in IBS patients vs. controls (p = 0.003).  
- Fecal propionate was significantly reduced in IBS patients vs. controls (p = 0.02).  
- Fecal acetate levels did not differ between groups (no p‑value reported, described as “similar”).  
- Butyrate concentration negatively correlated with IBS‑SSS scores (r = ‑0.42, p = 0.004).  
- IBS patients showed depletion of *Faecalibacterium prausnitzii* and *Roseburia* species, both recognized butyrate producers.  
- No significant differences in alpha diversity (Shannon index, observed ASVs) between groups.

**6. Limitations**:  
- Authors acknowledge the cross‑sectional design, which precludes establishing causality.  
- Authors note recruitment from a single clinical center, limiting generalizability.  
- Apparent limitations not discussed in the text: lack of data on diet, medication use, or other confounders; absence of longitudinal or interventional data; no mechanistic experiments linking SCFA changes directly to symptom generation.

**7. Open Questions**:  
- Does reduced SCFA production drive IBS symptoms, or is it a consequence of altered gut physiology/microbiota?  
- What are the longitudinal dynamics of SCFA levels and microbiota in IBS patients over time?  
- Can therapeutic strategies that increase butyrate (e.g., prebiotics, probiotics, direct supplementation) ameliorate IBS symptoms?  
- How do specific microbial taxa (*Faecalibacterium prausnitzii*, *Roseburia*) contribute to SCFA production in the gut ecosystem, and can their restoration normalize SCFA levels?

**8. Relevance to My Work**:  
The study demonstrates a functional link between microbial metabolite output (particularly butyrate) and gut‑related symptom severity in humans. For my mouse models, this suggests that measuring fecal or cecal SCFA concentrations could serve as a read‑out of microbiome‑mediated gut health. Interventions aimed at boosting butyrate‑producing bacteria or supplementing butyrate may be worthwhile to test for amelioration of experimentally induced gut dysfunction, mirroring the observed human association. Additionally, the depletion of specific butyrate‑producing genera highlights candidate taxa to monitor or manipulate in murine studies.
````

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-26 to speed T4 review. An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Output covers all required sections. Suggests specific therapeutic-strategy follow-up questions and emphasizes cecal SCFA measurement for mouse models. Complete, no truncation. Strong cross-model agreement.

**Suggested verdict (UNCONFIRMED):** Pass

**What still needs human verification:**
- Whether the recommended prebiotics/probiotics/supplementation list is appropriate
- Spot-check cited claims against source
- That the cecal-vs-fecal distinction is correctly characterized

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
